Search clinical trials for: D2 lymphadenectomy

Total 1240 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia

Schizophrenia
Shaheed Zulfiqar Ali Bhutto Medical University

Completed

Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke

Aspiration Pneumonia | Acute Stroke

Pakistan
Xian-Janssen Pharmaceutical Ltd.

Completed

A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia

Schizophrenia

China
Janssen-Cilag Farmaceutica Ltda.

Completed

Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate

Schizophrenia

Colombia, Mexico, Brazil
Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag International NV

Completed

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Schizophrenia

United States, Ukraine, Romania, South Africa, Taiwan, Korea, Republic of, Russian Federation, Costa Rica, Mexico
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Schizoaffective Disorder | Psychotic Disorder

United States, India, Malaysia, Romania, Korea, Republic of, Philippines
Johnson & Johnson Pte Ltd

Completed

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

Schizophrenia

Australia, China, Hong Kong, Taiwan, Malaysia, Korea, Republic of, New Zealand, Thailand, Philippines
Johnson & Johnson Taiwan Ltd

Completed

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Schizophrenia
Xian-Janssen Pharmaceutical Ltd.

Completed

A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics

Schizophrenia

China
Huazhong University of Science and Technology

Unknown

The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk

Schizophrenia

China
Janssen Korea, Ltd., Korea

Completed

Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission (PERFECT)

Schizophrenia

Korea, Republic of
Janssen-Cilag Turkey

Completed

A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

Schizophrenia

Turkey
Janssen Pharmaceutical K.K.

Completed

A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia

Schizophrenia
Janssen-Cilag Pty Ltd

Completed

An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia

Schizophrenia
University of Maryland, Baltimore

Withdrawn

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

Schizophrenia

United States
Janssen Korea, Ltd., Korea

Completed

Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants (PASS)

Schizophrenia

Korea, Republic of
Janssen Korea, Ltd., Korea

Completed

Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants (Power)

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.

Schizophrenia
Janssen-Cilag Pty Ltd

Completed

Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)

Schizophrenia

Australia
Johnson & Johnson Pte Ltd

Completed

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia (PREVAIL)

Schizophrenia

China, Taiwan, Malaysia, Korea, Republic of
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

Schizophrenia

Taiwan, Japan, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia

Schizophrenia
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Mayo Clinic

Completed

Assessment of Combined Bowel Preparation for Capsule Endoscopy Study (CEPREP)

Gastrointestinal Hemorrhage

United States
Janssen-Cilag International NV

Completed

Paliperidone Palmitate Flexible Dosing in Schizophrenia (PALMFlexS)

Schizophrenia

France, Ukraine, United Kingdom, Germany, Spain, Israel, Portugal, Turkey, Greece, Sweden, Belgium, Netherlands, Hungary, Denmark, Lithuania, Latvia, Croatia, Estonia, Austria, Switzerland
Janssen-Cilag International NV

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PERFlexS)

Schizophrenia

France, United Kingdom, Belgium, Germany, Spain, Portugal, Bulgaria, Serbia, Switzerland, Israel, Finland, Greece, Sweden, Russian Federation, Netherlands, Denmark, Hungary, Lithuania, Latvia, Croatia, Turkey, Poland
Seoul National University Hospital
Johnson & Johnson

Completed

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Schizophrenia

Korea, Republic of
Yale University

Withdrawn

Effects of Paliperidone in Posttraumatic Stress Disorder (PTSD)

Posttraumatic Stress Disorder

United States
Chonbuk National University Hospital
Janssen Korea, Ltd., Korea

Completed

Efficacy and Safety of Paliperidone ER in First Episode Psychosis

First Episode Psychosis

Korea, Republic of
Janssen Research & Development, LLC

Completed

An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia

Schizophrenia

China
University of South Florida
Indiana University; Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

Obsessive-Compulsive Disorder

United States
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Schizophrenia

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine

Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Study of the Relative Bioavailability of Paliperidone ER Formulations With Different Release Profiles and a Comparison to Paliperidone IR

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Dose Proportionality of Extended Release Paliperidone

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients

Schizophrenia | Insomnia
Hoffmann-La Roche

Completed

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Rheumatoid Arthritis

Denmark, Finland, Norway, Sweden
Ikechukwu Bartholomew Ulasi

Completed

The Effects of Combined Gum-chewing and Parenteral Metoclopramide on Post-operative Ileus

Ileus Postoperative

Nigeria
Emory University
National Institute on Drug Abuse (NIDA)

Recruiting

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 (VNS in OUD UH3)

Opioid Use Disorder | Opioid Use | Withdrawal Symptoms

United States
Duke University

Completed

Metoclopramide Versus Placebo for GJ Placement

Enteral Nutrition | Radiation Exposure

United States
Maosheng Fang

Unknown

The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia

Schizophrenia
Janssen Research & Development, LLC

Completed

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

Psychotic Disorders | Schizophrenia | Schizophrenic Disorders | Dementia Praecox

United States, Belgium, Poland, Bulgaria, India, Romania, Russian Federation, Ukraine, Korea, Republic of, Estonia, Finland
National Taiwan University Hospital

Unknown

A Pharmacokinetic Study of Paliperidone ER

Schizophrenia | Schizoaffective Disorder

Taiwan
Janssen Scientific Affairs, LLC

Completed

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Schizoaffective Disorder

United States, Ukraine, Bulgaria, India, Malaysia, Romania, South Africa, Philippines

3

Subscribe